Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East Tech Today.
Press releases published on April 24, 2025
IBEX Limited to Announce Third Quarter 2025 Financial Results on May 8th, 2025
GlobeNewswire
·
April 24, 2025
WASHINGTON, April 24, 2025 (GLOBE NEWSWIRE) -- IBEX Limited (“ibex”) (Nasdaq: IBEX), a leading global provider of business process outsourcing (BPO) and customer engagement technology solutions, today announced it will report third quarter 2025 financial …
Atico Reports Consolidated Financial Results for 2024
GlobeNewswire
·
April 24, 2025
(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year …
BIO-key Regains Compliance with Nasdaq Listing Rules After Receiving Notice of Non-Compliance
GlobeNewswire
·
April 24, 2025
HOLMDEL, N.J. , April 24, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound …
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
GlobeNewswire
·
April 24, 2025
-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 -- -- CB-010 …
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
GlobeNewswire
·
April 24, 2025
TORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system …
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 24, 2025
Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a first installment of €130 million and (ii) the debt …
GENFIT : Résultats financiers annuels 2024 et point sur les activités de la Société
GlobeNewswire
·
April 24, 2025
Trésorerie et équivalents de trésorerie s’élevant à 81,8 millions d’euros au 31 décembre 2024. En outre, conclusion, en début d’année (i) d’un accord de royalty financing non dilutif d'un montant maximum de 185 millions d'euros comprenant un versement …
SPS Commerce Reports First Quarter 2025 Financial Results
GlobeNewswire
·
April 24, 2025
Company delivers 97th consecutive quarter of topline growth First quarter 2025 revenue grew 21% and recurring revenue grew 23% from the first quarter of 2024 MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- SPS Commerce, Inc. (NASDAQ: SPSC), a leader in …
Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The …
Definitive Healthcare Announces Timing of Its First Quarter 2025 Financial Results Conference Call and Webcast
GlobeNewswire
·
April 24, 2025
FRAMINGHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its first quarter …
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)
GlobeNewswire
·
April 24, 2025
GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …
FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances
GlobeNewswire
·
April 24, 2025
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced the publication of a groundbreaking paper in the journal Science Advances detailing the development …
Seer to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
April 24, 2025
REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 …
Century Aluminum Sets Date for First Quarter 2025 Earnings Announcement
GlobeNewswire
·
April 24, 2025
CHICAGO, April 24, 2025 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) will report first quarter 2025 earnings on Wednesday, May 7, 2025, after market close. The news release will be issued through GlobeNewswire. The company will hold a follow …
AppFolio, Inc. Announces First Quarter 2025 Financial Results
GlobeNewswire
·
April 24, 2025
SANTA BARBARA, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- AppFolio, Inc. (NASDAQ: APPF) ("AppFolio" or the "Company"), a technology leader powering the future of the real estate industry, today announced its financial results for the first quarter ended …
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
GlobeNewswire
·
April 24, 2025
Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation …
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
GlobeNewswire
·
April 24, 2025
► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological …
Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor
GlobeNewswire
·
April 24, 2025
► Des signatures de biomarqueurs ont été développées pour prédire la réponse histologique au traitement par lanifibranor chez les patients atteints de MASH avec fibrose ► Les signatures de biomarqueurs développées pour l’amélioration de la fibrose, la …
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
GlobeNewswire
·
April 24, 2025
COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday, May 1, 2025, after the close of the U.S. financial …
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
GlobeNewswire
·
April 24, 2025
LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 …